Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy

References

• Cancer Stat Facts: Common Cancer Sites. Surveillance, epidemiology, and end results (SEER) program 2020 2020 Sept 25; Available from: https://www.cancer.gov/about-cancer/understanding/statistics.
   Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, Adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723.
   PubMed Web of Science ®Google Scholar
• June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med. 2015;7(280): 280ps7.
   Web of Science ®Google Scholar
• Filley AC, Henriquez M, Dey M. CART immunotherapy: development, success, and translation to Malignant Gliomas and other solid tumors. Front Oncol. 2018;8:453.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.
   PubMed Web of Science ®Google Scholar
• Davila ML, Brentjens R, Wang X, et al. How do CARs work?: early insights from recent clinical studies targeting CD19. Oncoimmunology. 2012;1(9):1577–1583.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Curran KJ. Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematology. 2012;2012(1):143–151.
   PubMedGoogle Scholar
• Wagner J, et al. CAR T cell therapy for solid tumors: bright future or dark reality? Mol Ther. 2020;28(11):2320–2339.
   PubMed Web of Science ®Google Scholar
• Sun S, Hao H, Yang G, et al. Immunotherapy with CAR-Modified T cells: toxicities and overcoming strategies. J Immunol Res. 2018;2018:2386187.
   PubMed Web of Science ®Google Scholar
• Paul S, Shilpi KN, et al. Intratumoral natural killer cells show reduced effector and cytolytic properties and control the differentiation of effector Th1 cells. OncoImmunology. 2016;5(12):e1235106.
   PubMed Web of Science ®Google Scholar
• Coca S, Perez-Piqueras J, Martinez D, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997;79(12):2320–2328.
   PubMed Web of Science ®Google Scholar
• Friese MA, Steinle A, Weller M. The innate immune response in the central nervous system and its role in glioma immune surveillance. Onkologie. 2004;27(5):487–491.
   PubMedGoogle Scholar
• Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16(1):7–19.
   PubMed Web of Science ®Google Scholar
• Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006;20(3):123–137.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Moretta F, Brescia L, et al. Natural killer cells in the treatment of high-risk acute leukaemia. Semin Immunol. 2014;26(2):173–179.
   PubMed Web of Science ®Google Scholar
• Simonetta F, Alvarez M, Negrin RS. Natural killer cells in graft-versus-host-Disease after allogeneic hematopoietic cell transplantation. Front Immunol. 2017;8:465.
   PubMed Web of Science ®Google Scholar
• Moretta L, Locatelli F, Pende D, et al. Killer Ig–like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood. 2011;117(3):764–771.
   PubMed Web of Science ®Google Scholar
• Yoon SR, Lee YS, Yang SH, et al. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant. 2010;45(6):1038–1046.
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051–3057.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28(6):955–959.
   PubMed Web of Science ®Google Scholar
• Scheper W, Gründer C, Straetemans T, et al. Hunting for clinical translation with innate-like immune cells and their receptors. Leukemia. 2014;28(6):1181–1190.
   PubMed Web of Science ®Google Scholar
• Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17(9):1025–1036.
   PubMed Web of Science ®Google Scholar
• Shembrey C, Huntington ND, Hollande F. Impact of tumor and immunological heterogeneity on the anti-cancer immune response. Cancers (Basel). 2019;11(9):1217.
   Web of Science ®Google Scholar
• Liu E, Tong Y, Dotti G, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520–531.
   PubMed Web of Science ®Google Scholar
• Ruella M, June CH. Chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for you. Curr Hematol Malig Rep. 2016;11(5):368–384.
   PubMed Web of Science ®Google Scholar
• Costello RT, Gastaut JA, Olive D. Tumor escape from immune surveillance. Arch Immunol Ther Exp (Warsz). 1999;47(2):83–88.
   PubMedGoogle Scholar
• Algarra I, Garc�a-lora A, Cabrera T, et al. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother. 2004;53(10):904–910.
   PubMed Web of Science ®Google Scholar
• Gumperz JE, Barber LD, Valiante NM, et al. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor. J Immunol. 1997;158(11):5237–5241.
   PubMed Web of Science ®Google Scholar
• Bauer S, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285(5428):727–729.
   PubMed Web of Science ®Google Scholar
• Cosman D, Müllberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14(2):123–133.
   PubMed Web of Science ®Google Scholar
• Das H, Groh V, Kuijl C, et al. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity. 2001;15(1):83–93.
   PubMed Web of Science ®Google Scholar
• Steinle A, Li P, Morris DL, et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics. 2001;53(4):279–287.
   PubMed Web of Science ®Google Scholar
• Boyington JC, Brooks AG, Sun PD. Structure of killer cell immunoglobulin-like receptors and their recognition of the class I MHC molecules. Immunol Rev. 2001;181(1):66–78.
   PubMedGoogle Scholar
• Boyington JC, Sun PD. A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Mol Immunol. 2002;38(14):1007–1021.
   PubMed Web of Science ®Google Scholar
• Jinushi M, Takehara T, Tatsumi T, et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer. 2003;104(3):354–361.
   PubMed Web of Science ®Google Scholar
• Yokoyama WM. Natural killer cell receptors. Curr Opin Immunol. 1995;7(1):110–120.
   PubMed Web of Science ®Google Scholar
• Santoni A, Carlino C, Stabile H, et al. REVIEW ARTICLE: mechanisms underlying recruitment and accumulation of decidual NK cells in uterus during pregnancy. Am J Reprod Immunol. 2008;59(5):417–424.
   PubMed Web of Science ®Google Scholar
• Metelitsa LS, Wu H-W, Wang H, et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med. 2004;199(9):1213–1221.
   PubMed Web of Science ®Google Scholar
• Thomas SY, Hou R, Boyson JE, et al. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J Immunol. 2003;171(5):2571–2580.
   PubMed Web of Science ®Google Scholar
• Van Helden MJ, Zaiss DM, Sijts AJ. CCR2 defines a distinct population of NK cells and mediates their migration during influenza virus infection in mice. PLoS One. 2012;7(12):e52027.
   PubMed Web of Science ®Google Scholar
• Chang AL, Miska J, Wainwright DA, et al. CCL2 produced by the Glioma microenvironment is essential for the recruitment of regulatory T cells and Myeloid-Derived suppressor cells. Cancer Res. 2016;76(19):5671–5682.
   PubMed Web of Science ®Google Scholar
• Lim SY, Yuzhalin AE, Gordon-Weeks AN, et al. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget. 2016;7(19):28697–28710.
   Google Scholar
• Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-Positive lymphoid tumors. N Engl J Med. 2020;382(6):545–553.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
   PubMed Web of Science ®Google Scholar
• Perales M-A, Kebriaei P, Kean LS, et al. Building a safer and faster CAR: seatbelts, airbags, and CRISPR. Biol Blood Marrow Transplant. 2018;24(1):27–31.
   PubMed Web of Science ®Google Scholar
• Herrera L, Santos S, Vesga MA, et al. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. Sci Rep. 2019;9(1):18729.
   PubMedGoogle Scholar
• Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664–679.
   PubMed Web of Science ®Google Scholar
• Porter DL, Hwang W-T, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62.
   PubMed Web of Science ®Google Scholar
• Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943–947.
   PubMed Web of Science ®Google Scholar
• Liu S, Deng B, Yin Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 2020;10(2):15.
   PubMed Web of Science ®Google Scholar
• Maziarz RT, CAR T-cell therapy total cost can exceed $1.5 million per treatment, in Healio. May 29, 2019: Immuno-Oncology Resource Center.
   Google Scholar
• Szabo L, Cascade of costs could push CAR-T therapy to $1.5M per patient, in ENDPOINTNEWS. 2017.
   Google Scholar
• Santomasso B, Bachier C, Westin J, et al. The other side of CAR T-Cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. American Society of Clinical Oncology Educational Book. 2019;39:433–444. doi: 10.1200/EDBK_238691.
   PubMedGoogle Scholar
• Hay AE, Cheung MC. CAR T-cells: costs, comparisons, and commentary. J Med Econ. 2019;22(7):613–615.
   PubMed Web of Science ®Google Scholar
• Staines R Natural killer cells ‘a hundred times cheaper’ than CAR-T. February 13, 2018; Available from: https://pharmaphorum.com/news/natural-killer-cancer-therapy-a-hundred-times-cheaper-than-car-t.
   Google Scholar
• Poli A, Michel T, Thérésine M, et al. CD56 bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458–465.
   PubMed Web of Science ®Google Scholar
• Jacobs R, Hintzen G, Kemper A, et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol. 2001;31(10):3121–3127.
   PubMed Web of Science ®Google Scholar
• Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol. 2013;132(3):536–544.
   PubMed Web of Science ®Google Scholar
• Malmberg K-J, Carlsten M, Björklund A, et al. Natural killer cell-mediated immunosurveillance of human cancer. Semin Immunol. 2017;31:20–29.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Rouce RH. The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol. 2015;6:578.
   PubMed Web of Science ®Google Scholar
• Wang W, et al. NK cell-Mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. 2015;6:368.
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44–49.
   PubMed Web of Science ®Google Scholar
• Xie G, Dong H, Liang Y, et al. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633–640.
   PubMed Web of Science ®Google Scholar
• Nagler A, Lanier LL, Cwirla S, et al. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol. 1989;143(10):3183–3191.
   PubMed Web of Science ®Google Scholar
• Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med. 2001;7(1):94–100.
   PubMed Web of Science ®Google Scholar
• Screpanti V, Wallin RPA, Ljunggren H-G, et al. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol. 2001;167(4):2068–2073.
   PubMed Web of Science ®Google Scholar
• López-Soto A, Gonzalez S, Smyth MJ, et al. Control of Metastasis by NK Cells. Cancer Cell. 2017;32(2):135–154.
   PubMed Web of Science ®Google Scholar
• Vivier E, Nunès JA, Vély F. Natural Killer Cell Signaling Pathways. Science. 2004;306(5701):1517–1519.
   PubMed Web of Science ®Google Scholar
• Yoon SR, Kim T-D, Choi I. Understanding of molecular mechanisms in natural killer cell therapy. Exp Mol Med. 2015;47(2):e141.
   PubMedGoogle Scholar
• Sordo-Bahamonde C, Lorenzo-Herrero S, Payer ÁR, et al. Mechanisms of apoptosis resistance to NK Cell-Mediated cytotoxicity in cancer. Int J Mol Sci. 2020;21(10):3726.
   Web of Science ®Google Scholar
• Topham NJ, Hewitt EW. Natural killer cell cytotoxicity: how do they pull the trigger? Immunology. 2009;128(1):7–15.
   PubMed Web of Science ®Google Scholar
• Foley B, Felices M, Cichocki F, et al. The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev. 2014;258(1):45–63.
   PubMed Web of Science ®Google Scholar
• Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5):495–502.
   PubMed Web of Science ®Google Scholar
• Thielens A, Vivier E, Romagné F. NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol. 2012;24(2):239–245.
   PubMed Web of Science ®Google Scholar
• Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell. 2010;142(6):847–856.
   PubMed Web of Science ®Google Scholar
• Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol. 2018;51:146–153.
   PubMed Web of Science ®Google Scholar
• Moretta A, Bottino C, Vitale M, et al. ACTIVATING RECEPTORS AND CORECEPTORS INVOLVED IN HUMAN NATURAL KILLER CELL-MEDIATED CYTOLYSIS. Annu Rev Immunol. 2001;19(1):197–223.
   PubMedGoogle Scholar
• Li Y, Yin J, Li T, et al. NK cell-based cancer immunotherapy: from basic biology to clinical application. Sci China Life Sci. 2015;58(12):1233–1245.
   PubMed Web of Science ®Google Scholar
• Bollino D, Webb TJ. Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy. Transl Res. 2017;187:32–43.
   PubMed Web of Science ®Google Scholar
• Cheng M, Chen Y, Xiao W, et al. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 2013;10(3):230–252.
   PubMed Web of Science ®Google Scholar
• Liu J, et al., Activating killer cell immunoglobulin-like receptor 2DS2 binds to HLA-A*11. Proceedings of the National Academy of Sciences, 2014. 111( 7): p. 2662–2667.
   Google Scholar
• Moretta L, Pietra G, Montaldo E, et al. Human NK cells: from surface receptors to the therapy of leukemias and solid tumors. Front Immunol. 2014;5(87). DOI:10.3389/fimmu.2014.00087.
   Google Scholar
• Cornel AM, Mimpen IL, Nierkens S. MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers (Basel). 2020;12(7):1760.
   PubMed Web of Science ®Google Scholar
• Kärre K. Immunology. A perfect mismatch. Science. 2002;295(5562):2029–2031.
   PubMed Web of Science ®Google Scholar
• Bradley M, Zeytun A, Rafi-Janajreh A, et al. Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells. Blood. 1998;92(11):4248–4255.
   PubMed Web of Science ®Google Scholar
• Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461–469.
   PubMed Web of Science ®Google Scholar
• Caldwell KJ, Gottschalk S, Talleur AC. Allogeneic CAR cell therapy-more than a pipe dream. Front Immunol. 2021;11:618427.
   PubMed Web of Science ®Google Scholar
• Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113(3):726–732.
   PubMed Web of Science ®Google Scholar
• Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411–2419.
   PubMed Web of Science ®Google Scholar
• Sekine T, Marin D, Cao K, et al. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 2016;128(2):297–312.
   PubMed Web of Science ®Google Scholar
• Venstrom JM, Pittari G, Gooley TA, et al. HLA-C–Dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med. 2012;367(9):805–816.
   PubMed Web of Science ®Google Scholar
• Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Iimmunol. 2014;192(10):4592–4600. Baltimore, Md.: 1950.
   PubMed Web of Science ®Google Scholar
• Allen ES, Stroncek DF, Ren J, et al. Autologous lymphapheresis for the production of chimeric antigen receptor T cells. Transfusion. 2017;57(5):1133–1141.
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Drexler HG. Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. Leuk Res. 2003;27(10):935–945.
   PubMed Web of Science ®Google Scholar
• Woll PS, Grzywacz B, Tian X, et al. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood. 2009;113(24):6094–6101.
   PubMed Web of Science ®Google Scholar
• Chouaib S, Pittari G, Nanbakhsh A, et al. Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies. Front Immunol. 2014;5:95.
   PubMed Web of Science ®Google Scholar
• Stringaris K, Sekine T, Khoder A, et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 2014;99(5):836–847.
   PubMed Web of Science ®Google Scholar
• Winters JL. Complications of donor apheresis. J Clin Apher. 2006;21(2):132–141.
   PubMed Web of Science ®Google Scholar
• Miller JP, Perry EH, Price TH, et al. Recovery and safety profiles of marrow and PBSC donors: experience of the national marrow donor program. Biol Blood Marrow Transplant. 2008;14(9 Suppl):29–36.
   PubMed Web of Science ®Google Scholar
• Yuan S, Ziman A, Smeltzer B, et al. Moderate and severe adverse events associated with apheresis donations: incidences and risk factors. Transfusion. 2010;50(2):478–486.
   PubMed Web of Science ®Google Scholar
• Knorr DA, Ni Z, Hermanson D, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013;2(4):274–283.
   PubMed Web of Science ®Google Scholar
• Ni Z, Knorr DA, Bendzick L, et al. Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells. 2014;32(4):1021–1031.
   PubMed Web of Science ®Google Scholar
• Spanholtz J, Preijers F, Tordoir M, et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One. 2011;6(6):e20740.
   PubMed Web of Science ®Google Scholar
• Suck G, Odendahl M, Nowakowska P, et al. NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother. 2016;65(4):485–492.
   PubMed Web of Science ®Google Scholar
• Romanski A, Uherek C, Bug G, et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med. 2016;20(7):1287–1294.
   PubMed Web of Science ®Google Scholar
• Oelsner S, Friede ME, Zhang C, et al. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy. 2017;19(2):235–249.
   PubMed Web of Science ®Google Scholar
• Kobayashi E, Kishi H, Ozawa T, et al. A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells. Biochem Biophys Res Commun. 2014;453(4):798–803.
   PubMed Web of Science ®Google Scholar
• Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8(4):652–658.
   PubMed Web of Science ®Google Scholar
• Mehta RS, Rezvani K. Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front Immunol. 2018;9:283.
   PubMed Web of Science ®Google Scholar
• Dalle J-H, Menezes J, Wagner É, et al. Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatr Res. 2005;57(5):649–655.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu H, Zheng X, et al. High expression of NKG2A/CD94 and low expression of granzyme B are associated with reduced cord blood NK cell activity. Cell Mol Immunol. 2007;4(5):377–382.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Kai S, Yamaguchi M, et al. Analysis of natural killer (NK) cell activity and adhesion molecules on NK cells from umbilical cord blood. Eur J Haematol. 2003;71(1):29–38.
   PubMed Web of Science ®Google Scholar
• Bradstock KF, Luxford C, Grimsley PG. Functional and phenotypic assessment of neonatal human leucocytes expressing natural killer cell-associated antigens. Immunol Cell Biol. 1993;71(Pt 6):535–542.
   PubMedGoogle Scholar
• Xing D, Ramsay AG, Gribben JG, et al. Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. J Immunother. 2010;33(7):684–696. Hagerstown, Md.: 1997.
   PubMed Web of Science ®Google Scholar
• Krampera M, Tavecchia L, Benedetti F, et al. Intracellular cytokine profile of cord blood T-, and NK- cells and monocytes. Haematologica. 2000;85(7):675–679.
   PubMed Web of Science ®Google Scholar
• Alnabhan R, Madrigal A, Saudemont A. Differential activation of cord blood and peripheral blood natural killer cells by cytokines. Cytotherapy. 2015;17(1):73–85.
   PubMed Web of Science ®Google Scholar
• Shaim H, Yvon E. Cord blood: a promising source of allogeneic natural killer cells for immunotherapy. Cytotherapy. 2015;17(1):1–2.
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Matsumoto-Kobayashi M, Clark SC, et al. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med. 1984;160(4):1147–1169.
   PubMed Web of Science ®Google Scholar
• Wagner J, Pfannenstiel V, Waldmann A, et al. A Two-Phase expansion protocol combining Interleukin (IL)-15 and IL-21 improves natural killer cell proliferation and cytotoxicity against Rhabdomyosarcoma. Front Immunol. 2017;8:676.
   PubMed Web of Science ®Google Scholar
• Carson WE, Fehniger TA, Haldar S, et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest. 1997;99(5):937–943.
   PubMed Web of Science ®Google Scholar
• Naume B, Gately M, Espevik T. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. J Immunol. 1992;148(8):2429–2436.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200–218.
   PubMed Web of Science ®Google Scholar
• Harada H, Watanabe S, Saijo K, et al. A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells. Exp Hematol. 2004;32(7):614–621.
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Riley JP, Dudley ME, et al. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011;17(19):6287–6297.
   PubMed Web of Science ®Google Scholar
• Klöß S, Oberschmidt O, Morgan M, et al. Optimization of human NK cell manufacturing: fully automated separation, improved Ex Vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-Expressing effector cells. Hum Gene Ther. 2017;28(10):897–913.
   PubMed Web of Science ®Google Scholar
• Granzin M, Stojanovic A, Miller M, et al. Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma. Oncoimmunology. 2016;5(9):e1219007.
   PubMed Web of Science ®Google Scholar
• Berg M, et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11(3):341–355.
   PubMed Web of Science ®Google Scholar
• Phillips JH, Lanier LL. A model for the differentiation of human natural killer cells. Studies on the in vitro activation of Leu-11+ granular lymphocytes with a natural killer-sensitive tumor cell, K562. J Exp Med. 1985;161(6):1464–1482.
   PubMed Web of Science ®Google Scholar
• Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106(1):376–383.
   PubMed Web of Science ®Google Scholar
• Lapteva N, Durett AG, Sun J, et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012;14(9):1131–1143.
   PubMed Web of Science ®Google Scholar
• Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69(9):4010–4017.
   PubMed Web of Science ®Google Scholar
• Fujisaki H, Kakuda H, Imai C, et al. Replicative potential of human natural killer cells. Br J Haematol. 2009;145(5):606–613.
   PubMed Web of Science ®Google Scholar
• Denman CJ, Senyukov VV, Somanchi SS, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One. 2012;7(1):e30264.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Schafer JR, Bassett R, et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017;130(16):1857–1868.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Coustan-Smith E, Kamiya T, et al. Expanded and armed natural killer cells for cancer treatment. Cytotherapy. 2016;18(11):1422–1434.
   PubMed Web of Science ®Google Scholar
• Gill S, Vasey AE, De Souza A, et al. Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood. 2012;119(24):5758–5768.
   PubMed Web of Science ®Google Scholar
• Werneck MB, Lugo-Villarino G, Hwang ES, et al. T-bet plays a key role in NK-mediated control of melanoma metastatic disease. J Immunol. 2008;180(12):8004–8010.
   PubMed Web of Science ®Google Scholar
• Townsend MJ, Weinmann AS, Matsuda JL, et al. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity. 2004;20(4):477–494.
   PubMed Web of Science ®Google Scholar
• Pearce EL, et al. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science. 2003;302(5647):1041–1043.
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z, Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proceedings of the National Academy of Sciences of the United States of America, 1989. 86( 24): p. 10024–10028.
   Google Scholar
• Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388–398.
   PubMed Web of Science ®Google Scholar
• Chang ZL, Chen YY. CARs: synthetic immunoreceptors for cancer therapy and beyond. Trends Mol Med. 2017;23(5):430–450.
   PubMed Web of Science ®Google Scholar
• Schubert ML, Hoffmann J-M, Dreger P, et al. Chimeric antigen receptor transduced T cells: tuning up for the next generation. Int J Cancer. 2018;142(9):1738–1747.
   PubMed Web of Science ®Google Scholar
• Kim MG, Kim D, Suh S-K, et al. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics. Arch Pharm Res. 2016;39(4):437–452.
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024–10028.
   PubMed Web of Science ®Google Scholar
• Wang J, Jensen M, Lin Y, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther. 2007;18(8):712–725.
   PubMed Web of Science ®Google Scholar
• Pfefferle A, Huntington ND. You have got a fast CAR: chimeric antigen receptor NK cells in cancer therapy. Cancers (Basel). 2020;12(3):706.
   Web of Science ®Google Scholar
• Wu CY, Roybal KT, Puchner EM, et al. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015;350(6258):aab4077.
   PubMed Web of Science ®Google Scholar
• Ruella M, Barrett DM, Kenderian SS, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016;126(10):3814–3826.
   PubMed Web of Science ®Google Scholar
• Grada Z, Hegde M, Byrd T, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2013;2(7):e105.
   PubMedGoogle Scholar
• Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest. 2016;126(8):3036–3052.
   PubMed Web of Science ®Google Scholar
• Lanitis E, Poussin M, Klattenhoff AW, et al. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in Vivo. Cancer Immunol Res. 2013;1(1):43–53.
   PubMed Web of Science ®Google Scholar
• Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31(1):71–75.
   PubMed Web of Science ®Google Scholar
• Roybal KT, Rupp L, Morsut L, et al. Precision tumor recognition by T cells with combinatorial Antigen-Sensing circuits. Cell. 2016;164(4):770–779.
   PubMed Web of Science ®Google Scholar
• Müller T, Uherek C, Maki G, et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother. 2008;57(3):411–423.
   PubMed Web of Science ®Google Scholar
• Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28(4):917–927.
   PubMed Web of Science ®Google Scholar
• Uherek C, Tonn T, Uherek B, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002;100(4):1265–1273.
   PubMed Web of Science ®Google Scholar
• Burger MC, Zhang C, Harter PN, et al. CAR-Engineered NK Cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy. Front Immunol. 2019;10(2683). DOI:10.3389/fimmu.2019.02683.
   Google Scholar
• Li Y, Hermanson DL, Moriarity BS, et al. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181–192.e5.
   PubMed Web of Science ®Google Scholar
• Altvater B, Landmeier S, Pscherer S, et al. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res. 2009;15(15):4857–4866.
   PubMed Web of Science ®Google Scholar
• Müller N, Michen S, Tietze S, et al. Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma. J Immunother. 2015;38(5):197–210.
   PubMed Web of Science ®Google Scholar
• Xiao L, Cen D, Gan H, et al. Adoptive transfer of NKG2D CAR mRNA-Engineered natural killer cells in colorectal cancer patients. Mol Ther. 2019;27(6):1114–1125.
   PubMed Web of Science ®Google Scholar
• Töpfer K, Cartellieri M, Michen S, et al. DAP12-Based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol. 2015;194(7):3201–3212.
   PubMed Web of Science ®Google Scholar
• Chang YH, Connolly J, Shimasaki N, et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013;73(6):1777–1786.
   PubMed Web of Science ®Google Scholar
• Guo C, Wang X, Zhang H, et al. Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells. Mol Immunol. 2019;114:108–113.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Fujisaki H, Cho D, et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy. 2012;14(7):830–840.
   PubMed Web of Science ®Google Scholar
• Chu Y, Hochberg J, Yahr A, et al. Targeting CD20+ aggressive B-cell Non–Hodgkin lymphoma by anti-CD20 CAR mRNA-Modified expanded natural killer cells in vitro and in NSG mice. Cancer Immunol Res. 2015;3(4):333–344.
   PubMed Web of Science ®Google Scholar
• Jiang H, Zhang W, Shang P, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol. 2014;8(2):297–310.
   PubMed Web of Science ®Google Scholar
• Chen KH, Wada M, Firor AE, et al. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget. 2016;7(35):56219–56232.
   PubMedGoogle Scholar
• Chen KH, Wada M, Pinz KG, et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia. 2017;31(10):2151–2160.
   PubMed Web of Science ®Google Scholar
• Sinha C, Seth A, Kahali B, et al. Development and Evaluation of NK-CD123 CAR against high risk acute myeloid leukemia. Biol Blood Marrow Transplant. 2017;23(3):S253.
   Web of Science ®Google Scholar
• Liu H, Yang B, Sun T, et al. Specific growth inhibition of ErbB2‑expressing human breast cancer cells by genetically modified NK‑92 cells. Oncol Rep. 2015;33(1):95–102. .
   PubMed Web of Science ®Google Scholar
• Kruschinski A, Moosmann A, Poschke I, et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A. 2008;105(45):17481–17486.
   PubMed Web of Science ®Google Scholar
• Schönfeld K, Sahm C, Zhang C, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 2015;23(2):330–338.
   PubMed Web of Science ®Google Scholar
• Han J, Chu J, Keung Chan W, et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of Glioblastoma and Patient-Derived Glioblastoma stem cells. Sci Rep. 2015;5(1):11483.
   PubMedGoogle Scholar
• Sahm C, Schönfeld K, Wels WS. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother. 2012;61(9):1451–1461.
   PubMed Web of Science ®Google Scholar
• Genßler S, Burger MC, Zhang C, et al. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunology. 2016;5(4):e1119354.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Ahmed M, Tassev DV, et al. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential. Leukemia. 2015;29(11):2238–2247.
   PubMed Web of Science ®Google Scholar
• Park H, Awasthi A, Ayello J, et al. ROR1-Specific Chimeric Antigen Receptor (CAR) NK cell immunotherapy for high risk neuroblastomas and sarcomas. Biol Blood Marrow Transplant. 2017;23(3):S136–S137.
   Web of Science ®Google Scholar
• Mhaidly R, Verhoeyen E. Humanized mice are precious tools for preclinical evaluation of CAR T and CAR NK cell therapies. Cancers (Basel). 2020;12(7):1915.
   Web of Science ®Google Scholar
• Olson B, Li Y, Lin Y, et al. Mouse models for cancer immunotherapy research. Cancer Discov. 2018;8(11):1358–1365.
   PubMed Web of Science ®Google Scholar
• Boissel L, Betancur M, Lu W, et al. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma. 2012;53(5):958–965.
   PubMed Web of Science ®Google Scholar
• Sutlu T, Nyström S, Gilljam M, et al. Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. Hum Gene Ther. 2012;23(10):1090–1100.
   PubMed Web of Science ®Google Scholar
• Boissel L, Betancur M, Wels WS, et al. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res. 2009;33(9):1255–1259.
   PubMed Web of Science ®Google Scholar
• Tassev DV, Cheng M, Cheung NK. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther. 2012;19(2):84–100.
   PubMed Web of Science ®Google Scholar
• Li L, Liu LN, Feller S, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther. 2010;17(3):147–154.
   PubMed Web of Science ®Google Scholar
• Afolabi LO, Adeshakin AO, Sani MM, et al. Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9. Immunology. 2019;158(2):63–69.
   PubMed Web of Science ®Google Scholar
• Rautela J, Surgenor E, Huntington ND. Efficient genome editing of human natural killer cells by CRISPR RNP. bioRxiv. 2018;406934.
   Google Scholar
• Naeimi Kararoudi M, Dolatshad H, Trikha P, et al. Generation of knock-out primary and expanded human NK cells using Cas9 Ribonucleoproteins. J Vis Exp. 2018(136). doi:10.3791/58237.
   PubMed Web of Science ®Google Scholar
• Shah NN, Baird K, Delbrook CP, et al. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell–depleted stem cell transplantation. Blood. 2015;125(5):784–792.
   PubMed Web of Science ®Google Scholar
• Rabinovich BA, Li J, Shannon J, et al. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J Immunol. 2003;170(7):3572–3576.
   PubMed Web of Science ®Google Scholar
• Cerboni C, Zingoni A, Cippitelli M, et al. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. Blood. 2007;110(2):606–615.
   PubMed Web of Science ®Google Scholar
• Olson JA, Leveson-Gower DB, Gill S, et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010;115(21):4293–4301.
   PubMed Web of Science ®Google Scholar
• Dominguez E, Lowdell MW, Perez-Cruz I, et al. Natural killer cell function is altered by freezing in DMSO. Biochem Soc Trans. 1997;25(2):175s.
   PubMed Web of Science ®Google Scholar
• Lapteva N, Szmania SM, Van Rhee F, et al. Clinical grade purification and expansion of natural killer cells. Crit Rev Oncog. 2014;19(1–2):121–132.
   PubMedGoogle Scholar
• Pasley S, Zylberberg C, Matosevic S. Natural killer-92 cells maintain cytotoxic activity after long-term cryopreservation in novel DMSO-free media. Immunol Lett. 2017;192:35–41.
   PubMed Web of Science ®Google Scholar
• Voshol H, Dullens HFJ, Otter WD, et al. Human natural killer cells: a convenient purification procedure and the influence of cryopreservation on cytotoxic activity. J Immunol Methods. 1993;165(1):21–30.
   PubMed Web of Science ®Google Scholar
• Domogala A, Madrigal JA, Saudemont A. Cryopreservation has no effect on function of natural killer cells differentiated in vitro from umbilical cord blood CD34(+) cells. Cytotherapy. 2016;18(6):754–759.
   PubMed Web of Science ®Google Scholar
• Koehl U, Brehm C, Huenecke S, et al. Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol. 2013;3:118.
   PubMedGoogle Scholar
• Fujiwara S, Mitoshi A, Michio Y, et al. Cryopreservation of human lymphocytes for assessment of lymphocyte subsets and natural killer cytotoxicity. J Immunol Methods. 1986;90(2):265–273.
   PubMed Web of Science ®Google Scholar
• Davis ZB, Felices M, Verneris MR, et al. Natural killer cell adoptive transfer therapy: exploiting the first line of defense against cancer. Cancer J. 2015;21(6):486–491.
   PubMed Web of Science ®Google Scholar
• Bachanova V, Cooley S, Defor TE, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014;123(25):3855–3863.
   PubMed Web of Science ®Google Scholar
• Antony GK, Dudek AZ. Interleukin 2 in cancer therapy. Curr Med Chem. 2010;17(29):3297–3302.
   PubMed Web of Science ®Google Scholar
• Conlon KC, Lugli E, Welles HC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2015;33(1):74–82.
   PubMed Web of Science ®Google Scholar
• Konstantinidis KV, Alici E, Aints A, et al. Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells. Exp Hematol. 2005;33(2):159–164.
   PubMed Web of Science ®Google Scholar
• Tam YK, Maki G, Miyagawa B, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther. 1999;10(8):1359–1373.
   PubMed Web of Science ®Google Scholar
• Jochems C, Hodge JW, Fantini M, et al. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. Oncotarget. 2016;7(52):86359–86373.
   PubMedGoogle Scholar
• Imamura M, Shook D, Kamiya T, et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood. 2014;124(7):1081–1088.
   PubMed Web of Science ®Google Scholar
• Liu E, Tong Y, Dotti G, et al. Cord blood derived natural killer cells engineered with a chimeric antigen receptor targeting CD19 and expressing IL-15 have long term persistence and exert potent anti-leukemia activity. Blood. 2015;126(23):3091.
   Web of Science ®Google Scholar
• Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity. 2019;50(4):924–940.
   PubMed Web of Science ®Google Scholar
• David CJ, Massagué J. Contextual determinants of TGFβ action in development, immunity and cancer. Nat Rev Mol Cell Biol. 2018;19(7):419–435.
   PubMed Web of Science ®Google Scholar
• Yu J, Wei M, Becknell B, et al. Pro- and antiinflammatory cytokine signaling: reciprocal Antagonism regulates Interferon-gamma production by human natural killer cells. Immunity. 2006;24(5):575–590.
   PubMed Web of Science ®Google Scholar
• Castriconi R, et al., Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proceedings of the National Academy of Sciences, 2003. 100( 7): p. 4120–4125.
   Google Scholar
• Regis S, Dondero A, Caliendo F, et al. NK cell function regulation by TGF-β-Induced epigenetic mechanisms. Front Immunol. 2020;11(311). DOI:10.3389/fimmu.2020.00311.
   PubMedGoogle Scholar
• Burga RA, Yvon E, Chorvinsky E, et al. Engineering the TGFβ receptor to enhance the therapeutic potential of natural killer cells as an Immunotherapy for Neuroblastoma. Clin Cancer Res. 2019;25(14):4400–4412.
   PubMed Web of Science ®Google Scholar
• Powell AB, Yadavilli S, Saunders D, et al. Medulloblastoma rendered susceptible to NK-cell attack by TGFβ neutralization. J Transl Med. 2019;17(1):321.
   PubMed Web of Science ®Google Scholar
• Yvon ES, Burga R, Powell A, et al. Cord blood natural killer cells expressing a dominant negative TGF-β receptor: implications for adoptive immunotherapy for glioblastoma. Cytotherapy. 2017;19(3):408–418.
   PubMed Web of Science ®Google Scholar
• Carrega P, Morandi B, Costa R, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer. 2008;112(4):863–875.
   PubMed Web of Science ®Google Scholar
• Zhang S, et al. Prognostic significance of tumor-Infiltrating natural killer cells in solid tumors: a systematic review and Meta-Analysis. Front Immunol. 2020;11(1242).
   Google Scholar
• Yilmaz A, et al. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. J Hematol Oncol. 2020;13(1):168.
   PubMed Web of Science ®Google Scholar
• Gras Navarro A, Björklund AT, Chekenya M. Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol. 2015;6(202). DOI:10.3389/fimmu.2015.00202
   PubMedGoogle Scholar
• Melero I, Rouzaut A, Motz GT, et al. T-Cell and NK-Cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 2014;4(5):522–526.
   PubMed Web of Science ®Google Scholar
• Habif G, Crinier A, André P, et al. Targeting natural killer cells in solid tumors. Cell Mol Immunol. 2019;16(5):415–422.
   PubMed Web of Science ®Google Scholar
• Lima M, Leander M, Santos M, et al. Chemokine receptor expression on normal blood CD56+NK-Cells elucidates cell partners that comigrate during the innate and adaptive immune responses and identifies a transitional NK-Cell population. J Immunol Res. 2015;2015:839684.
   PubMed Web of Science ®Google Scholar
• Zou Y, Li F, Hou W, et al. Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells. Br J Cancer. 2014;110(8):1992–1999.
   PubMed Web of Science ®Google Scholar
• Wang J, Matosevic S. Functional and metabolic targeting of natural killer cells to solid tumors. Cell Oncol. 2020;43(4):577–600.
   Web of Science ®Google Scholar
• Halama N, Braun M, Kahlert C, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res. 2011;17(4):678–689.
   PubMed Web of Science ®Google Scholar
• Vianello F, Papeta N, Chen T, et al. Murine B16 melanomas expressing high levels of the chemokine stromal-Derived factor-1/CXCL12 induce tumor-Specific T cell chemorepulsion and escape from immune control. J Immunol. 2006;176(5):2902–2914.
   PubMed Web of Science ®Google Scholar
• Wendel M, Galani IE, Suri-Payer E, et al. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 2008;68(20):8437–8445.
   PubMed Web of Science ®Google Scholar
• Kremer V, Ligtenberg MA, Zendehdel R, et al. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. J Immunother Cancer. 2017;5(1):73.
   PubMedGoogle Scholar
• Mgrditchian T, Arakelian T, Paggetti J, et al. Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner. Proc Natl Acad Sci U S A. 2017;114(44):E9271–e9279.
   PubMed Web of Science ®Google Scholar
• Chen X, Han J, Chu J, et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget. 2016;7(19):27764–27777.
   PubMedGoogle Scholar
• Hou W, Chen H, Rojas J, et al. Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF. Int J Cancer. 2014;135(5):1238–1246.
   PubMed Web of Science ®Google Scholar
• Sampath P, Li J, Hou W, et al. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol Ther. 2013;21(3):620–628.
   PubMed Web of Science ®Google Scholar
• Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–38043.
   PubMed Web of Science ®Google Scholar
• Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269–281.
   PubMed Web of Science ®Google Scholar
• Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced Non–Small cell lung cancer: results of the PEMBRO-RT Phase 2 randomized clinical trial. JAMA Oncol. 2019;5(9):1276–1282.
   PubMed Web of Science ®Google Scholar
• Xie G, Gu D, Zhang L, et al. A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma. Cancer Biol Ther. 2017;18(8):547–551.
   PubMed Web of Science ®Google Scholar
• Bernstein MB, Krishnan S, Hodge JW, et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016;13(8):516–524.
   PubMed Web of Science ®Google Scholar
• Gasser S, Orsulic S, Brown EJ, et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436(7054):1186–1190.
   PubMed Web of Science ®Google Scholar
• Khan M, Arooj S, Wang H. NK cell-Based immune checkpoint inhibition. Front Immunol. 2020;11:167.
   PubMed Web of Science ®Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130–3144.
   PubMed Web of Science ®Google Scholar
• John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. OncoImmunology. 2013;2(10):e26286.
   PubMed Web of Science ®Google Scholar
• Chong EA, Melenhorst JJ, Lacey SF, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR. Blood. 2017;129(8):1039–1041.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38.
   PubMed Web of Science ®Google Scholar
• Suarez ER, Chang D-K, Sun J, et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016;7(23):34341–34355.
   Google Scholar
• Rafiq S, Yeku OO, Jackson HJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847–856.
   PubMed Web of Science ®Google Scholar
• Lanuza PM, Pesini C, Arias MA, et al. Recalling the biological significance of immune checkpoints on NK cells: a chance to overcome LAG3, PD1, and CTLA4 inhibitory pathways by adoptive NK cell transfer? Front Immunol. 2020;10(3010). DOI:10.3389/fimmu.2019.03010.
   PubMedGoogle Scholar
• Hsu J, Hodgins JJ, Marathe M, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 2018;128(10):4654–4668.
   PubMed Web of Science ®Google Scholar
• Oyer JL, Gitto SB, Altomare DA, et al. PD-L1 blockade enhances anti-tumor efficacy of NK cells. OncoImmunology. 2018;7(11):e1509819.
   PubMed Web of Science ®Google Scholar
• Daher M, Basar R, Gokdemir E, et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021;137(5):624–636.
   PubMed Web of Science ®Google Scholar
• Wang X, Jasinski DL, Medina JL, et al. Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells. Blood Adv. 2020;4(9):1950–1964.
   PubMed Web of Science ®Google Scholar
• Pfefferle A, Jacobs B, Netskar H, et al. Intra-lineage plasticity and functional reprogramming maintain natural killer cell repertoire diversity. Cell Rep. 2019;29(8):2284–2294.e4.
   PubMed Web of Science ®Google Scholar